Key Highlights

  • MYGN traded around $3.19 at last closing, with a market Capitalization near $305 million.
  • Second-quarter 2026 Revenue fell 11% year over year to about $190.7 million, with test volumes down 1%.
  • Piper Sandler double-downgraded the stock to Underweight, cutting its price target to $2 from $5.45.
  • The company suspended its adjusted EBITDA guidance while narrowing full-year revenue guidance to $770-$790 million.

Myriad Genetics has become one of 2026's more closely tracked diagnostics turnaround stories, and not for flattering reasons. After a steep share-price decline and a wave of analyst downgrades, the molecular-diagnostics veteran enters the autumn trading near multi-year lows, with investors focused squarely on whether its product launches can stabilize revenue. The next catalysts are concrete and dated, which makes the setup easier to frame than most.

Company and Latest Development

Myriad Genetics, Inc. (NASDAQ:MYGN) is a molecular diagnostics company known for hereditary cancer testing, the GeneSight pharmacogenomic test, prenatal screening and tumor profiling. The pivotal recent development came with its second-quarter 2026 results, reported July 30, 2026: revenue of about $190.7 million, an 11% year-over-year decline, with test volumes down 1% to roughly 379,000 and average revenue per test down about 9%. The company guided full-year 2026 revenue to $770-$790 million and adjusted gross Margin of 66-67%, while suspending its prior adjusted EBITDA guidance. Shares fell sharply following the report.

What Is Driving Attention Around MYGN?

Unlike many names in this coverage, MYGN's move has an identifiable driver. The Q2 report and suspended EBITDA guidance triggered a pronounced sell-off and a cascade of analyst actions. Piper Sandler issued a rare double-downgrade to Underweight, cutting its price target to $2 from $5.45; Stephens lowered its target to $3 while keeping an Equal Weight rating amid a 40%-plus share decline; and UBS assumed coverage at Neutral with a $3.60 target. The debate centers on Myriad's path back to sustainable profitability after softer volumes and pricing.

Key Numbers and Company Position

MYGN traded around $3.19 at last closing, with a market capitalization near $305 million. Verified figures from the July 30 report include second-quarter revenue of roughly $190.7 million (down 11% year over year), about 379,000 tests performed, full-year revenue guidance of $770-$790 million and adjusted gross margin guidance of 66-67%, with adjusted EBITDA guidance suspended. During 2026 the company launched Prolaris with AI-based digital pathology for prostate cancer, expanded its Precise MRD offering to additional tumor types, and rolled out the FirstGene prenatal screen.

What Could Come Next?

The nearest scheduled catalyst is Myriad's appearance at the 21st Annual Wells Fargo Healthcare Conference on September 10, 2026, where management may address strategy and margins. Beyond that, third-quarter 2026 results, historically reported in early November, loom as the key test of whether revenue trends stabilize. Investors may also watch commercial uptake of Prolaris with AI, Precise MRD expansion and FirstGene, along with any reinstatement of profitability guidance or cost actions.

Risks to Watch

The risks are pointed. Declining revenue and pricing pressure raise questions about Myriad's competitive position in a crowded genetic-testing market, where reimbursement dynamics can compress average revenue per test. The suspension of adjusted EBITDA guidance signals reduced near-term Earnings visibility. A share price near multi-year lows can weigh on sentiment and financing flexibility. Execution on new-product launches is unproven at scale, and continued Volume softness or margin erosion could pressure the stock further.

A Diagnostics Reset Still Searching for a Floor

Myriad Genetics offers a clearly defined setup: a diagnostics Franchise with recognized brands and fresh product launches, set against declining revenue, suspended profitability guidance and a deeply negative analyst tape. The September 10 Wells Fargo conference and early-November third-quarter results will help investors judge whether the reset is bottoming or still unfolding, with price targets ranging from $2 to $3.60.